ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L2

A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study

Petra C.E. Hissink Muller1,2, D.M.C. Brinkman1,3, Dieneke Schonenberg4, Yvonne Koopman-Keemink5, J. Merlijn Van den Berg6, W.P. Bekkering7, Marion van Rossum8,9, Lisette WA van Suijlekom-Smit10, Cornelia F. Allaart11 and Rebecca ten Cate1, 1Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Pediatric Rheumatology, Reade, Amsterdam, Netherlands, 3Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 5Pediatrics, Haga ziekenhuis, The Hague, Netherlands, 6Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 7Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, 8Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 9Reade, Amsterdam, Netherlands, 10Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, 11Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologics, DMARDs, juvenile idiopathic arthritis (JIA), methotrexate (MTX) and treatment

  • Tweet
  • Email
  • Print
Session Information

Session Title: ACR Late-breaking Abstracts Session

Session Type: Late-Breaking Abstracts

Background/Purpose:

BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time to flare after DMARD discontinuation, ACRpedi scores, functional ability, safety, and radiological damage. Follow up will be 2 years. Here we present the 3 months clinical outcome of the initial treatments.

Methods:

Recent onset, DMARD naïve JIA patients (Rheumatoid Factor-negative polyarticular, oligoarticular or with psoriasis (ILAR-criteria), < 18 months symptom duration) were randomized (per center, variable blocks) to 3 treatment strategies: 1. sequential DMARD-monotherapy (starting with sulfasalazine (SSZ) 50mg/kg/day or methotrexate (MTX) 10mg/m2/week, based on physician’s preference), 2.  combination therapy: MTX 10mg/m2/week and 4 weeks prednisolone-bridging 0.5mg/kg/day, in 2 weeks tapered to nil, and 3. combination therapy with MTX 10mg/m2/week and etanercept 0.8mg/kg/wk.

MTX was combined with folic acid 5mg/week. NSAIDs and intra-articular steroids are permitted in all patients. Treatment adjustments were made every 3 months after assessment by a trained examiner who remained unaware of allocated treatment group. Target was ACRpedi50 after 3 months and from 6 months of follow-up and onwards the treatment target was inactive disease.

Results:

From October 2009 to April 2014, 95 children, of which 33% boys, were enrolled: 32 in  arm 1, 32 in arm 2 and 31 in arm 3. Baseline median (IQR) age was 9.1 (4.7-12,9) years. 38% were ANA positive, 12 patients had oligoarticular disease, 68 patients oligoextended/polyarticular JIA and 15 patients had JIA with psoriasis. Baseline median (IQR) ACRpedi scores: VAS physician 49 (40-58) mm, VAS patient 54 (37-70) mm, ESR 6,5 (2-14,8)  mm/hr, number of active joints 8 (5-12), number of joints with limited range of motion 3 (1-5), CHAQ score 0,88 (0,63-1,5).  In arm 1, 18/32 had started with MTX, the others with SSZ. One patient in arm 1 (lost to FU) and 1 in arm 3 (uveitis) dropped out before 3 months. Complete visits were included for analysis.

By 3 months ACRpedi30 was reached by 14/31 (45%), 15/31 (48%), 20/29 (69%) of patients in arms 1-3, respectively (p=0.14). ACRpedi50 was reached by 7/31 (23%), 12/31 (39%) and 15/29 (52%) (p=0.065, arm 1 vs 2 p=0.17, 2 vs 3 p=0.31, 1 vs 3 p=0.019) and ACRpedi70 was reached by 3/31 (10%), 5/31 (16%) and 10/29 (34%) in arms 1-3, respectively (p=0.045, arm 1 vs 2 p=0.45, 2 vs 3 p=0.10, 1 vs 3 p=0.020).   

Toxicity (mainly gastrointestinal complaints) was similar in the treatment arms. No serious adverse events were reported. In 2/32, 1/32 and 2/31 patients MTX dose was reduced or switched to subcutaneous and 3/18 patients stopped SSZ after 6 weeks because of nausea, malaise and headache.

Conclusion:

After 3 months of initial treatment in a three-armed strategy trial, patients with recent onset JIA achieve more clinical improvement (significantly more ACRpedi50 and 70) on initial combination therapy with MTX and etanercept than on initial MTX or SSZ monotherapy. Numerically, response to initial treatment with MTX and prednisolone bridging seems more effective than monotherapy and less effective than combination with etanercept, but these differences were not statistically significant.


Disclosure:

P. C. E. Hissink Muller,

Pfizer Inc,

3;

D. M. C. Brinkman,
None;

D. Schonenberg,
None;

Y. Koopman-Keemink,
None;

J. M. Van den Berg,
None;

W. P. Bekkering,
None;

M. van Rossum,

Pfizer Inc,

2,

Pfizer Inc,

9;

L. W. van Suijlekom-Smit,

Dutch Arthritis Association,

2,

Pfizer, Roche, Novartis,

5,

Pfizer Inc, Bristol-Myers Squibb,

9;

C. F. Allaart,
None;

R. ten Cate,

Pfizer Inc,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-comparison-of-three-treatment-strategies-in-recent-onset-dmard-naive-juvenile-idiopathic-arthritis-3-months-results-of-the-best-for-kids-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.